secwatch.observer — SEC 8-K summary
======================================

Issuer:     TScan Therapeutics, Inc. (TCRX)
CIK:        0001783328
Form:       8-K
Filed at:   2023-03-31T23:59:59+00:00
Accession:  0001193125-23-086922
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TScan CEO David Southwell steps down; Gavin MacBeath named acting CEO
---------------------------------------------------------------------

- David Southwell resigned as CEO, President, and Board member effective March 27, 2023; no disagreement with company.
- Gavin MacBeath, Ph.D., appointed acting CEO effective March 28, 2023; will continue as Chief Scientific and Operating Officer.
- Southwell receives 18 months salary continuation and COBRA; severance conditioned on release and compliance with restrictive covenants.
- Company reaffirms cash runway into Q2 2024 with $120M cash as of Dec 31, 2022; clinical programs on track.
- First patient dosed with TSC-101 on March 9, 2023; plans to provide preliminary safety/biomarker data by mid-year 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783328/000119312523086922/0001193125-23-086922-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783328/000119312523086922/d477438d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-086922

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer